Risk of macrosomia remains glucose-dependent in a cohort of women with pregestational type 1 diabetes and good glycemic control

Katarzyna Cyganek¹ · Jan Skupien² · Barbara Katra¹,² · Alicja Hebda-Szydło¹,² · Izabela Janas³ · Iwona Trznadel-Morawska¹,² · Przemysław Witek¹,² · Elżbieta Kozek¹,² · Maciej T. Malecki¹,²

Received: 5 July 2016 / Accepted: 22 September 2016 / Published online: 11 October 2016 © The Author(s) 2016; This article is published with open access at Springerlink.com

Abstract Macrosomia risk remains high in type 1 diabetes (T1DM) complicated pregnancies. A linear relationship between macrosomia risk and glycated hemoglobin A1c (HbA1c) was described; however, low range of HbA1c has not been studied. We aimed to identify risk factors and examine the impact of HbA1c on the occurrence of macrosomia in newborns of T1DM women from a cohort with good glycemic control. In this observational retrospective one-center study we analyzed records of 510 consecutive T1DM pregnancies (1998–2012). The analyzed group consisted of 375 term singleton pregnancies. We used multiple regression models to examine the impact of HbA1c and self-monitored glucose in each trimester on the risk of macrosomia and birth weight. The median age of T1DM women was 28 years, median T1DM duration—11 years, median pregestational BMI—23.3 kg/m². Median birth weight reached 3520 g (1st and 3rd quartiles 3150 and 3960, respectively) at median 39 weeks of gestation. There were 85 (22.7 %) macrosomic (>4000 g) newborns. Median HbA1c levels in the 1st, 2nd, and 3rd trimester were 6.4, 5.7, and 5.6 %. Third trimester HbA1c, mean fasting self-monitored glucose and maternal age were independent predictors of birth weight and macrosomia. There was a linear relationship between 3rd trimester HbA1c and macrosomia risk in HbA1c range from 4.5 to 7.0 %. Macrosomia in children of T1DM mothers was common despite excellent metabolic control. Glycemia during the 3rd trimester was predominantly responsible for this condition.

Keywords Type 1 diabetes · Pregnancy · Macrosomia · Glycated hemoglobin A1c

Introduction

Diabetes is the most common metabolic disease complicating pregnancy [1, 2]. It is associated with increased risk of maternal and neonatal complications and constitutes a serious medical, social, and financial problem. There is ample evidence that regardless of diabetes type, hyperglycemia during pregnancy increases risk of adverse outcomes [3, 4]. Today pregnant women with type 1 diabetes (T1DM) can achieve a very good glycemic control, however, despite substantial improvements in diabetes care, the rate of complications, and particularly macrosomia, remains high [5–8]. Fetal macrosomia is associated with an increased risk of cesarean section, injuries to the birth canal and to the fetus, as well as obesity and metabolic diseases later in life [9–13].

The HAPO study (Hyperglycemia and Adverse Pregnancy Outcomes) revealed that there was no risk threshold in the association of fetal macrosomia and glycemia measured during an oral glucose tolerance test performed in pregnant women without pregestational diabetes [14]. This observation, together with another clinical trial of glucose lowering treatment in mild gestational diabetes [15], have led to conclusion that therapeutic measures to decrease blood glucose in pregnancy should be addressed to a larger

Katarzyna Cyganek and Jan Skupien equally contributed to this work.

Maciej T. Malecki malecki_malecki@yahoo.com

¹ Department of Metabolic Diseases, University Hospital, Krakow, Poland
² Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland
population of pregnant women. It subsequently resulted in a substantial change of diagnostic criteria of gestational diabetes worldwide. In pregestational diabetes the target hemoglobin A1c (HbA1c) during pregnancy is generally defined at a close to normal level, for example <6.5% (<47 mmol/mol) according to The National Institute for Health and Care Excellence [16] or within the range of 6.0–6.5% (42–47 mmol/mol) according to the current standards of diabetes care of The American Diabetes Association [17]. In the light of the HAPO study results, one can hypothesize that there is an analogous continuous relationship between birth weight and HbA1c level in women with T1DM. This association could be present for HbA1c values below 6% (42 mmol/mol), prompting reconsideration of current therapeutic targets.

We have earlier reported that women with T1DM achieved excellent glycemic control in the 2nd and 3rd trimesters of pregnancy, regardless of their insulin treatment regimen—multiple daily injections or personal insulin pump [18]. In the current observational study we describe the relationship between maternal HbA1c, self-monitored glucose and macrosomia risk in this group, and attempt to verify the hypothesis that macrosomia remains a glucose-dependent complication of pregnancy in women with T1DM, in spite of achievement of therapeutic goals.

Subjects and methods

Subjects

This retrospective, observational, cross-sectional cohort study was performed at the Department of Metabolic Diseases of the University Hospital, Krakow, Poland, an academic referral center for diabetes care in South-Eastern Poland. All pregnant women with pre-existing T1DM were registered between the years 1998 and 2012 as a continuous case series. They were all referred to the Department no later than in the 1st trimester of pregnancy and had a clinical diagnosis of T1DM established at least one year prior to conception. The patients were Caucasian residents of South-Eastern Poland.

The study protocol and its conduct were concordant with the Helsinki Declaration and it was approved and supervised by the Jagiellonian University Bioethical Committee.

All women with diabetes who were pregnant or planned pregnancy received intensive diabetes management care in the clinic as described earlier [18]. That management involved education on diet and physical activity, glycemic goals and self-monitoring of blood glucose (SMBG), with self-adjustment of insulin dose. According to the Polish Diabetes Association recommendations at the time when the study was performed [19], the therapeutic targets for all women were: (a) HbA1c < 6.1% (43 mmol/mol), (b) fasting self-monitored glucose 60–90 mg/dl, and (c) subsequent pre- and 1-h postprandial self-monitored within 60–120 mg/dl. Pregnancy planning was defined as described earlier [18]. Briefly, the term “pregnancy planning” refers to the time of entry to our intensive diabetes management program and applies to women who entered this program before conception.

Clinical characteristics of the women, information on the course of pregnancy and glycemic control markers were collected during regular clinic visits. Diabetic retinopathy was diagnosed by fundoscopy at a visit scheduled during the 1st trimester and diabetic nephropathy was diagnosed with urinary albumin and serum creatinine (eGFR) according to KDIGO guidelines [20]. Pregnancy outcomes were ascertained during a postpartum visit and from medical records. Birth weight was recorded for all term pregnancies. Macrosomia was defined as birth weight >4000 g.

HbA1c was measured with high performance liquid chromatography (HLPC) on a Variant apparatus (Biorad) and was DCCT adjusted. The inter- and intra-assay coefficient of variation was less than 2%. The clinical laboratory in which HbA1c was measured participates in an internal and external quality control program by regularly performing calibration procedures and blind assays of standardized material.

In each trimester the patient-provided SMBG profile was recorded during a study visit—it included measurements from 7 days preceding the visit. The measurements recorded were typically at least 8 times a day: before and 60 min after every meal, additionally at bedtime and between 2–4 am. Corresponding timed non-missing measurements from consecutive days were averaged. The following variables were extracted or calculated from SMBG profiles in each trimester: mean fasting glucose, mean glucose (arithmetic mean of all measurements), mean postprandial glucose (arithmetic mean of postprandial measurements) and mean glucose amplitude (average difference between the highest and the lowest daily glucose measurement).

Statistical analyses

For descriptive purposes the data is presented as medians (1st, 3rd quartile) and mean ± standard deviation (SD). Statistical comparisons between macrosomia and normal birth weight groups were performed with the Wilcoxon test, chi-square test of Fisher exact test, where applicable.

To identify independent risk predictors of macrosomia we used multiple logistic regression analysis. The complete list of independent variables included: maternal age, T1DM duration, presence of diabetic retinopathy or nephropathy, maternal weight and BMI before conception, weight gain during pregnancy, HbA1c recorded in each of three
trimesters, mean fasting self-monitored glucose, mean daily self-monitored glucose, mean postprandial self-monitored glucose and mean SMBG amplitude, treatment with continuous subcutaneous insulin infusion (CSII) and pregnancy planning. We performed a supervised best subset selection of candidate variables by minimizing Bayesian Information Criterion. We controlled collinearity with variance inflation and monitored the confounding properties of predictors. In the final model we retained all nominally significant predictors. In addition, the predictors from the final logistic model were evaluated with multiple linear regression model for their association with birth weight as a continuous variable. As a sensitivity analysis we fitted multiple logistic and linear regression models to data restricted to women who in all three trimesters had HbA1c < 6.5 % (48 mmol/mol), the current American Diabetes Association (ADA) and National Institute for Health and Clinical Excellence (NICE) target; a similar analysis was done for HbA1c < 6.1 % (43 mmol/mol) during the entire pregnancy.

To dissect how risk of macrosomia depends on different levels of HbA1c in the 3rd trimester we stratified the distribution of this marker and calculated risk of macrosomia in each stratum. First, for graphical assessment we divided the cohort into six arbitrary groups. An apparent risk increase above HbA1c of 5.6 % (38 mmol/mol) was tested with a logistic spline model. Then, to obtain a smooth plot of the relationship between HbA1c and macrosomia risk we divided the HbA1c distribution into 15 equal strata, each containing 25 women. For each stratum we calculated mean 3rd trimester HbA1c and probability of macrosomia. We used a penalized low-rank thin-plate spline model [21] fitted to a scatter of 15 macrosomia probabilities by mean 3rd trimester HbA1c, with knots placed at a regular distance of a 0.3 percentage point between HbA1c 4.5 and 7.5 % (26–59 mmol/mol, 11 knots). The posterior probabilities of model parameters were estimated through Gibbs sampling (an example of Markov chain Monte Carlo algorithm). We used non-informative priors and initial values of fixed-effect parameters were estimated using restricted maximum likelihood. We used 30,000 burn-in iterations, and 100,000 iterations for inference, of which we saved 10,000. Convergence was assessed by visual inspection of trace plots and density plots from 4 parallel chains, autocorrelation of time-series and Gelman–Rubin diagnostic.

The analysis was performed with SAS 9.3 software (Cary, NC, USA), OpenBUGS 3.2.3, R software 3.1.0 (The R Foundation for Statistical Computing, Vienna, Austria) using SemiPar and R2OpenBUGS packages. P-values <0.05 were considered significant.

**Results**

The exclusion criteria and causes of dropout from the initial sample size of 510 consecutive patients are presented in Fig. 1. Briefly, 16 women had incomplete follow-up and/or missing outcome data, 9 were excluded due to multiple pregnancy, in 110 women the pregnancy ended before the 37th week. The final analysis included 375 woman–child pairs. The baseline characteristics of the study population are presented in Table 1. The median age at first pregnancy visit was 28 years and T1DM duration was 11 years. The mothers had generally adequate body weight, with median BMI 23.3 kg/m². Consistently with long T1DM duration, prevalence of retinopathy was 25.6 %. None of the patients showed evidence of chronic kidney disease of stage 3 or higher.

Less than one half (41.6 %) of the women entered the intensive diabetes care program (pregnancy planning). Most patients during pregnancy were treated with rapid-acting insulin analogs (60.3 %) and predominantly used insulin pumps (58.9 %). HbA1c decreased systematically during the gestational period: from median 6.4 % (46 mmol/mol) in the first trimester to 5.7 % (39 mmol/mol) and

![Fig. 1 Numbers of patients initially accessed, excluded and included in the study](image)
Table 1 Characteristics of the study group

| Characteristics                                      | Median (1st, 3rd quartile) and mean ± standard deviation or count (%) | P-value* |
|------------------------------------------------------|------------------------------------------------------------------------|----------|
|                                                      | No macrosomia N = 291 | Macrosomia N = 84 | Odds ratio (95 % CI) |
| Maternal baseline characteristics                    |                          |                        |                      |
| Age (years)                                          | 28 (25, 31)              | 27 (24, 30)            | 0.76 (0.58, 0.99)    | 0.026 |
| Diabetes duration (years)                            | 11 (5, 18)               | 10 (5, 16)             | 0.86 (0.72, 1.02)    | 0.13  |
| BMI before conception (kg/m²)                        | 23.2 (21.7, 25.6)        | 23.6 (22.0, 25.7)      | 1.04 (0.97, 1.11)    | 0.22  |
| Retinopathy                                          | 82 (28.2 %)              | 14 (16.6 %)            | 0.51 (0.27, 0.95)    | 0.033 |
| Nephropathy                                          | 5 (1.7 %)                | 2 (2.4 %)              | 1.39 (0.27, 7.32)    | 0.66  |
| Treatment during pregnancy                           |                          |                        |                      |
| Pregnancy planning                                   | 122 (41.9 %)             | 34 (40.5 %)            | 1.07 (0.65, 1.78)    | 0.81  |
| Analog insulin                                       | 174 (59.8 %)             | 52 (61.9 %)            | 1.08 (0.66, 1.79)    | 0.73  |
| CSII                                                 | 164 (56.4 %)             | 57 (67.9 %)            | 1.63 (0.98, 2.70)    | 0.059 |
| Glycemic control in 1st trimester                    |                          |                        |                      |
| HbA1c (%) (mmol/mol)                                 | 6.3 (5.7, 7.2)           | 6.9 (6.0, 7.5)         | 1.13 (0.94, 1.35)    | 0.029 |
| Mean SMBG glucose (mmol/l)                           | 5.9 (5.4, 6.4)           | 6.0 (5.5, 6.8)         | 1.06 (0.88, 1.26)    | 0.50  |
| Mean fasting glucose (mmol/l)                        | 5.5 (4.6, 6.5)           | 6.1 (5.0, 7.2)         | 1.13 (1.00, 1.28)    | 0.012 |
| Glycemic control in the 2nd trimester                |                          |                        |                      |
| HbA1c (%) (mmol/mol)                                 | 5.6 (5.1, 6.2)           | 6.0 (5.4, 6.5)         | 1.43 (1.12, 1.83)    | 0.002 |
| Mean SMBG glucose (mmol/l)                           | 5.6 (5.2, 6.0)           | 6.0 (5.5, 6.4)         | 1.45 (1.14, 1.85)    | <0.001|
| Mean fasting glucose (mmol/l)                        | 5.1 (4.5, 5.8)           | 5.7 (4.9, 6.4)         | 1.42 (1.18, 1.71)    | <0.001|
| Glycemic control in the 3rd trimester                |                          |                        |                      |
| HbA1c (%) (mmol/mol)                                 | 5.5 (5.1, 6.0)           | 6.0 (5.4, 6.5)         | 1.81 (1.36, 2.41)    | <0.001|
| Mean SMBG glucose (mmol/l)                           | 5.7 (5.1, 6.2)           | 5.9 (5.4, 6.5)         | 1.48 (1.15, 1.92)    | 0.001 |
| Mean fasting glucose (mmol/l)                        | 5.0 (4.4, 5.7)           | 5.4 (4.9, 6.4)         | 1.52 (1.24, 1.87)    | <0.001|
| Follow-up outcomes                                   |                          |                        |                      |
| Duration of pregnancy (weeks)                        | 39 (38, 40)              | 39 (39, 41)            | 1.22 (1.03, 1.43)    | 0.029 |
| Weight gain during pregnancy (kg)                    | 15 (11, 19)              | 16 (11, 19)            | 1.01 (0.97, 1.05)    | 0.32  |
| Cesarean deliveries                                  | 198 (68.0 %)             | 53 (63.1 %)            | 0.83 (0.49, 1.41)    | 0.40  |
| Birth weight (g)                                     | 3370 (3060, 3650)        | 4290 (4155, 4565)      | –                    | <0.001|

*Comparison of medians or frequencies in macrosomia vs. no macrosomia
5.6 % (38 mmol/mol) in the second and third trimesters, respectively.

The proportion of women, who reached the therapeutic goal of HbA1c < 6.1 % (43 mmol/mol) increased significantly from 36.5 % (137 women) in the 1st trimester to 67.2 % (252) and 71.5 % (268 women) in the 2nd and 3rd trimester, respectively. The distribution of HbA1c in the 3rd trimester is shown in Fig. 2a. The trend of improving glycemic control was paralleled, to a lesser degree, by changes in mean daily glucose level indices from SMBG records in the 1st, 2nd, and 3rd trimester: median 5.9, 5.7, and 5.7 mmol/l, respectively, and by mean fasting glucose in SMBG records: 5.6, 5.2 and 5.1 mmol/l, respectively. The median weight gain of the women during pregnancy was 15 kg.

By design we analyzed term pregnancies; the median duration of gestation was 39 weeks. Most (66.9 %) pregnancies ended with cesarean delivery. The median birth weight was 3520 g. There were 84 (22.4 %) cases of macrosomia (>4000 g), a large proportion despite excellent glycemic control, especially in the 2nd and 3rd trimesters. However, more severe macrosomia was infrequent: there were 22 newborns (5.9 %) weighting >4500 g and only one with birth weight >5000 g. In comparison, among 70 cases of preterm deliveries (20th to 36th week, excluded from the further analysis) the median birth weight was 2900 g and there were only 5 cases of macrosomia.

In Table 1 we present comparison between woman–offspring pairs with and without macrosomia. Mothers of newborns with macrosomia were slightly younger (median 27 vs. 28 years, \( p = 0.026 \)) and had longer (\( p = 0.029 \)) duration of pregnancy, but did not differ from the rest in diabetes duration or BMI. Diabetic retinopathy at baseline had lower prevalence in mothers of macrosomic newborns (16.6 vs. 28.2 %). There were no differences in diabetes care: rates of pregnancy planning and insulin use were similar. Mothers of macromomic newborns (with borderline significance: \( p = 0.059 \)) were treated more frequently with personal insulin pumps (67.9 vs. 56.4 %). The most important difference between the macrosomia and non-macrosomia groups was observed for HbA1c, especially in the 2nd and 3rd trimesters: 6.0 % (42 mmol/mol) vs. 5.6 % (38 mmol/mol), \( p < 0.001 \) and 6.0 % (42 mmol/mol) vs. 5.5 % (37 mmol/mol), \( p < 0.001 \), respectively. Similarly, we observed differences in the 2nd and 3rd trimester (but not the 1st trimester) in mean self-monitored glucose: 6.0 vs. 5.6 mmol/l (\( p < 0.001 \)) and 5.9 vs. 5.7 mmol/l (\( p = 0.001 \)), respectively. Similar differences were observed for mean postprandial glucose in self-monitoring, which was highly correlated with mean glucose. No significant differences were observed for mean glucose amplitude. There was also a significant difference across all three trimesters between mean fasting self-monitored glucose. In the 1st trimester it was 6.1 vs. 5.5 mmol/l (\( p = 0.012 \)), in the 2nd it was 5.7 vs. 5.1 mmol/l (\( p < 0.001 \)), and in the 3rd trimester it was 5.4 vs. 5.0 mmol/l (\( p < 0.001 \)).

In order to define a set of predictors that independently contribute to the risk of macrosomia in our cohort we used a logistic regression model. The resulting set of variables is shown in Table 2. Gestational age, within the examined range of 37 to 45 weeks, was strongly associated with birth weight. One additional week of pregnancy increased the odds of macrosomia 1.3-fold (\( p = 0.010 \)). Maternal age (but not T1DM duration) was associated with lower risk of macrosomia (odds ratio 0.72 per 5 years increase, \( p = 0.027 \)). The mother’s baseline (first visit) weight (but not BMI) was associated with a 1.13-fold increase in odds of macrosomia (per 5 kg increase), with borderline significance (\( p = 0.054 \)), and this variable was retained in the final model for its possible confounding properties. The strongest predictor of birth weight was HbA1c recorded in the 3rd trimester. Its 1 percentage point increase was associated with a 1.68-fold increase in odds of macrosomia (\( p = 0.001 \)). Independently from HbA1c, the level of mean fasting glucose (measured with personal glucose meter) in the 3rd trimester was associated with a 1.38-fold increase in odds of macrosomia (per 1 mmol/l increase, \( p = 0.005 \)). There was no statistically independent association of mean blood glucose, mean glucose amplitude or mean postprandial glucose from SMBG records and risk of macrosomia. No marker of glycemia from the 1st or 2nd trimester had significant effect in the presence of the 3rd trimester markers.

We also evaluated the predictors listed in Table 2 for their association with birth weight. The results are consistent with the findings from the logistic models. Briefly, in the model adjusted for maternal age, gestational age and the mother’s baseline weight, an increase of HbA1c by 1 percentage point was associated with a 136 g higher birth weight (\( p < 0.001 \)), and in addition, a 1 mmol/l increase in mean fasting glucose (SMBG) was associated with a 100 g increase in birth weight (\( p < 0.001 \)), independently from HbA1c.

As a sensitivity analysis, we restricted our study group to women whose HbA1c was < 6.5 % (48 mmol/mol) in all three trimesters. There were 184 such women, and the risk of macrosomia in this subgroup was 16.3 %. Third trimester HbA1c remained a significant predictor of macrosomia (odds ratio 2.87, 95 % CI: 1.17, 7.03, \( p = 0.022 \)) when adjusted for maternal age, gestational age and the mother’s baseline weight. It remained significantly associated with birth weight (247 g increase per 1 % HbA1c increase, 95 % CI: 95, 399; \( p = 0.002 \)). In 124 women with HbA1c < 6.1 % (43 mmol/mol) there were too few cases of macrosomia (\( n = 17 \)) to fit a multiple logistic model, but birth
weight remained dependent from 3rd trimester HbA1c (259 g increase per 1 % HbA1c increase, 95 % CI: 55, 464; p = 0.013).

To further dissect the relationship between the birth weight and HbA1c in the 3rd trimester, for illustrative purpose, we estimated macrosomia risk in six arbitrary strata of HbA1c, as shown in Fig. 2b. Although there was an apparent increase in macrosomia risk in women with HbA1c >5.6 % (38 mmol/mol), there was no statistically significant difference in association between macrosomia and HbA1c below and above this threshold (p = 0.15). To formally determine the shape of the relationship between HbA1c in the 3rd trimester and macrosomia and establish a possible target value of this marker we estimated the risk of this complication in 15 strata containing 25 women each, ranked by HbA1c. We plotted the risks against mean HbA1c level in each stratum (black dots in Fig. 2c) and fitted a Bayesian penalized splines model to this scatter. It provided a continuous, nonlinear functional description of the relationship between HbA1c and macrosomia risk with 95 % Bayesian credible interval (black line and gray area, respectively in Fig. 2c). Inspection of this relationship reveals that it is linear in the HbA1c range from 4.5–7.0 % (26 to 53 mmol/mol). In this HbA1c range, the Bayesian estimate of macrosomia risk increase per 1 % increase in HbA1c was 12.7 percentage points. The risk of macrosomia predicted from our data (Fig. 2c) for the 3rd trimester HbA1c 6.0 % (42 mmol/mol) was approximately 25 %. The risk was 10 % for HbA1c level <5.0 % (31 mmol/mol).

Discussion

This large observational one-center study has demonstrated high (above 20 %) prevalence of macrosomia in T1DM-complicated pregnancies. This phenomenon occurred in spite of achieving the HbA1c goal of <6.1 % in the 2nd and 3rd trimester by the majority of women.

A quarter century ago, the St Vincent’s Declaration established, among many others, the goal of improving outcomes of pregnancies complicated by diabetes to make them comparable with those observed in non-diabetic women [22]. In spite of this, as proven in many clinical observations, macrosomia (defined either as birth weight above 4000 g or above the 90th percentile) is still very common in T1DM pregnancies with prevalence of 20–50 % [5, 8, 23]. Moreover, there has been very little evidence for the reduction of this most common neonatal outcome of T1DM-complicated pregnancy. There were reports from several European countries showing no significant decrease between surveys performed at different time points over the last two decades [24–26]. A rare example of an improvement was reported from Ireland, where the Irish Atlantic Diabetes in Pregnancy (ATLANTIC DIP) group representing five antenatal centers coordinated specialized care for women with diabetes before, during, and after
pregnancy [27]. This group reported a 30 % drop from the initial number of neonates born with macrosomia in women with T1DM [28]. However, their initial HbA1c level was substantially higher than in our cohort.

Our finding not only confirms but also broadens and deepens the conclusions of a study [23] performed in the population of Northern England (Northern Diabetes in Pregnancy Survey, NORDIP), where the risk of large for gestational age (LGA) birth weight increased steeply and monotonically with HbA1c in the range of 5.5–7.0 % (37–53 mmol/mol). In our study group the median HbA1c levels in the 2nd and 3rd trimester were 1 % lower than it was recorded in the NORDIP study. Thus, we can extend this observation towards the lower tail of HbA1c distribution. To avoid possible impact of arbitrary stratification of HbA1c distribution and random variation, we used a penalized thin-plate spline model to obtain a flexible functional representation of the relationship between the 3rd trimester HbA1c and macrosomia. Such function can adapt to possible non-linear relationships, thresholds and plateaus in analyzed data. We were unable to identify any risk threshold in HbA1c distribution. There was a linear relationship between the 3rd trimester HbA1c and the risk of macrosomia, starting from values of this marker as low as 4.5 % (26 mmol/mol). In our patients the risk of macrosomia was elevated (more than 10 %) for HbA1c >5.0 % (31 mmol/mol). Interestingly, as in the NORDIP study, the risk levelled for HbA1c values >7.0 % (53 mmol/mol). The risk levels, however, cannot be compared directly between that study and ours, because we used macrosomia, rather than percentile chart-based LGA and SGA (small for gestational age) births.

In a recently published analysis of the relationship between pregnancy complications and HbA1c in the Diabetes and Pre-eclampsia Intervention Trial (DAPIT) population the risks of LGA births in strata of 2nd and 3rd trimester HbA1c were strikingly similar to the ones observed in the NORDIP study [29]. There was a similar linear increase of risk followed by a plateau for HbA1c values >7.0 % (53 mmol/mol). To the best of our knowledge NORDIP and DAPIT are the only cohorts in which linearity of the association between LGA and HbA1c in pregestational diabetes has been formally explored. The unique value of our study is that it includes a large number (184) of women with HbA1c during all pregnancy below the current widely used therapeutic target of 6.5 %. Our results strongly suggest that macrosomia risk remains glucose-dependent for HbA1c levels that are significantly lower. Our finding can be also corroborated by the results of the HAPO study, which has shown that macrosomia risk can be increased in women with OGTT glucose values previously perceived as normal.

The strongest and the most consistent predictor of macrosomia is 3rd trimester HbA1c. In the SMBG profile association independent from HbA1c was observed only for mean fasting glucose. Neither mean glucose amplitude nor postprandial SMBG glucose were associated with macrosomia, and mean glucose was a much weaker predictor than HbA1c. This likely reflects deficiency of glucometer measurements in capturing all the variability of glucose levels. Another possible—although probably less likely—explanation could be the self-reporting nature of analyzed measurements and preferential inclusion of in-target glucose values by the patients.

The main finding of our study prompts urgent need for further research into effective means of glucose monitoring in pregnancy and contradicts the recent shift of target HbA1c in pregnancy from <6.0 % (42 mmol/mol) to <6.5 % (47 mmol/mol) by NICE and ADA [16, 17]. Despite improvements in diabetes management, macrosomia rates in T1DM are consistently reported as at least two-fold higher than in the general population. Attaining currently recommended HbA1c level does not prevent LGA births and, as a therapeutic target, it is misleading. HbA1c values >4.5 % (26 mmol/mol) remain associated with macrosomia risk, however, decreasing HbA1c to <6.0 % (42 mmol/mol), values comparable with observed in the non-diabetic general population [30] is not feasible in clinical practice. There is an urgent need to improve the standards of glucose

| Predictor | Association with risk of macrosomia (logistic model) | Association with birth weight (linear regression model) |
|-----------|-------------------------------------------------------|--------------------------------------------------------|
| Duration of pregnancy (increase by 1 week) | 1.27 (1.06, 1.52) | 0.010 | 90 (53, 127) | <0.001 |
| Mother’s age (increase by 5 years) | 0.72 (0.53, 0.96) | 0.027 | −78 (~136, −21) | 0.008 |
| Mother’s baseline weight (increase by 5 kg) | 1.13 (1.00, 1.27) | 0.054 | 30 (4, 56) | 0.022 |
| 3rd trimester HbA1c (increase by 1 %) | 1.68 (1.22, 2.32) | 0.001 | 136 (69, 204) | <0.001 |
| 3rd trimester mean fasting glucose (increase by 1 mmol/l) | 1.38 (1.10, 1.72) | 0.005 | 100 (54, 147) | <0.001 |

In linear regression effect estimates indicate change of predicted birth weight in grams CI confidence interval

Table 2 Predictors of macrosomia in multiple logistic model analysis and their association with birth weight in multiple regression model analysis
monitoring during pregnancy, possibly with wider use of continuous glucose monitoring. Alternative markers of hyperglycemia, such as 1,5-anhydroglucitol, which, according to our earlier finding [31], was a better marker of maternal glycemic control and predictor of neonatal birth weight than HbA1c in pregnancies complicated by T1DM, may possibly find wider application.

This study has several potential shortcomings. It is just observational research, meaning it is prone to some typical biases, for example some missing data or unprecise self-reported glucose measurements. Such biases could possibly alter the study results, for example by underestimating the association between the mean glucose amplitude and the risk of macrosomia. We believe that our study is representative for the T1DM population of the Lesser Poland region, however, we could not exclude that some women remained under medical care elsewhere and did not participate in this study. This is, however, unlikely as medical care of pregnant T1DM women in Poland is centralized and it is strongly recommended to refer the patients during pregnancy planning or at the latest in early pregnancy to tertiary reference centers like the Department of Metabolic Diseases in Krakow. Additionally, two limitations related to laboratory diagnostics should be acknowledged. First, there were different types of glucose meters used by the patients from our study over the period of 15 years. Nevertheless, these were devices from leading global manufacturers, all of them meeting European accuracy standards. We also did not control factors potentially affecting the HbA1c level during complicated pregnancy, such as iron or folic acid deficiency anemia. While we cannot entirely exclude the influence of these factors on the study results, this seems to be unlikely.

There are two more important issues that should be discussed. We chose to use as the outcome macrosomia defined as birth weight above 4000 g rather than LGA (large for gestational age) weight. This was related to several factors. First, we are lacking methodologically correct percentile charts from the Polish population for the study period. Second, there are scientific arguments for such a choice, since the 4 kg cut-off is a clinically important indicator of potential complications [8, 23, 26]. Additionally, possible injuries in the newborn or to the birth canal depend more on the absolute rather than relative size of a fetus. Moreover, although LGA is widely used in many countries, its definition relies on the quality and accuracy of percentile charts, which may differ between particular regions or time periods. A 4 kg cutoff is easy to compare between different studies. Finally, we study only term pregnancies and, additionally, adjust the risk of macrosomia in the regression models to gestational age. The second issue is related to the fact that both maternal weight and BMI were used as candidate independent variables. We assumed that birth weight may depend not only on mother’s body fat, but possibly also on her overall body size. Our analysis showed that maternal pregestational weight, unlike BMI, was indeed associated with birth weight.

In summary, despite an in-target HbA1c level in most women, the risk of macrosomia remains high in pregestational T1DM, and it remains a glucose-dependent complication. Our study suggests inadequacy of HbA1c and self-monitoring, as they apparently miss significant episodes of hyperglycemia.

Acknowledgments The authors thank Aleksandra Malecka from the Jagiellonian University for English language advice during preparation of this manuscript. This work was supported by the Polish Ministry of Science Grant No. N N407 414436 and by the Jagiellonian University Medical College.

Author contributions KC, MTM: study design, protocol development; KC, BK, AHS, ITM, PW, EK: searching medical databases; KC, JS: data analysis; KC, JS, BK, AHS, ITM, PW, EK, MTM: research data, data interpretation; KC, JS, MTM: writing the manuscript; BK, AHS, ITM, PW, EK: critical review of the manuscript; MTM: project coordination, final approval of the manuscript. MTM is the guarantor of the data and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Compliance with ethical standards

Conflict of interest The authors declare that they have no competing interests

Ethical approval The study was conducted in accordance with the Declaration of Helsinki, and an independent ethics committee.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. G. Danaei, M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, C.J. Paciorek, J.K. Lin, F. Farzadfarn, Y.H. Khang, G.A. Stevens, M. Rao, M.K. Ali, L.M. Riley, C.A. Robinson, M. Ezzati; on behalf of the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose), National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378, 31–40 (2011)
2. R. Bell, K. Bailey, T. Cresswell, G. Hawthorne, J. Critchley, N. Lewis-Barned; Northern Diabetic Pregnancy Survey Steering Group, Trends in prevalence and outcomes of pregnancy in women with pre-existing type I and type II diabetes. BJOG 115, 445–452 (2008)
3. DCCT Investigators, Pregnancy outcomes in the diabetes control and complications trial. AJOG 174, 1343–1353 (1996)
4. M. Balsells, A. García-Patterson, I. Gich, R.N. Corcoy, Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. JCEM 94, 4284–4291 (2009)
5. I. Evers, H. de Valk, B. Mol, E. ter Braak, G. Visser, Macrosomia despite good glycaemic control in Type I diabetic pregnancy; results of a nationwide study in The Netherlands. Diabetologia 45, 1484–1489 (2002)
6. L. Suhonen, V. Hiilesmaa, K. Teramo, Glycaemic control during early pregnancy and fetal malformations in women with type 1 diabetes mellitus. Diabetologia 43, 79–84 (2000)
7. Diabetes and Pregnancy Group, France, French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care 26, 2990–2993 (2003)
8. R.C. Temple, V. Aldridge, H.R. Murphy, Prepregnancy care and pregnancy outcomes in women with type 1 diabetes. Diabetes Care 29, 1744–1749 (2006)
9. D.F. Lewis, M.S. Edwards, T. Asrat, C.D. Adair, G. Brooks, S.J. London, Can shoulder dystocia be predicted? Preconception and prenatal factors. J. Reprod. Med. 43, 654–658 (1998)
10. M.A. Berk, F. Mimouni, M. Miodovnik, V. Hertzberg, J. Valuck, Macrosomia in infants of insulin-dependent diabetic mothers. Pediatrics 83, 1029–1034 (1989)
11. J.L. Ballard, B. Rosenn, J.C. Khoury, M. Miodovnik, Diabetic fetal macrosomia: significance of disproportionate growth. J Pediatrics 122, 115–119 (1993)
12. M. Rijpma, J.M. Evers, M.A. de Vroede, H.W. de Valk, C.J. Heijnen, G.H. Visser. Risk factors for childhood overweight in offspring of type 1 diabetic women with adequate glycemic control during pregnancy: nationwide follow-up study in the Netherlands. Diabetes Care 32, 2099–2104 (2009)
13. P.A. Weiss, H.S. Scholz, J. Haas, K.F. Tamussino, J. Seissler, M.H. Borkenstein, Long-term follow-up of infants of mothers with type 1 diabetes: evidence for hereditary and nonhereditary transmission of diabetes and precursors. Diabetes Care 23, 905–911 (2000)
14. The HAPO Study Cooperative Research Group, Hyperglycemia and adverse pregnancy outcomes. NEJM 358, 1991–2002 (2008)
15. M.B. Landon, C.Y. Spong, E. Thom, M.W. Carpenter, S.M. Ramin, B. Casey, National Institute of child health and human development maternal-fetal medicine units network. A multicenter, randomized trial of treatment for mild gestational diabetes. NEJM 361, 1339–1348 (2009)
16. NICE guideline. National Institute for Health and Care Excellence (2015). Diabetes in pregnancy: management Diabetes in pregnancy: management from preconception to the postnatal from preconception to the postnatal period. https://www.nice.org.uk/guidance/ng3. Accessed 25 February 2015
17. American Diabetes Association. Standards of medical care in diabetes – 2015. Diabetes Care 38, S1–S93 (2015)
18. K. Cyganek, A. Hebda-Szydlo, B. Katra, J. Skupien, T. Klupa, I. Janas, I. Kaim, J. Sieradzki, A. Reron, M.T. Malecki, Glycemic control and selected pregnancy outcomes in type 1 diabetes women on continuous subcutaneous insulin infusion and multiple daily injections: the significance of pregnancy planning. Diabetes Technol. Ther. 12, 41–47 (2010)
19. Polish Diabetes Association, The clinical guidelines in patients with diabetes. Diabet. Prakt. 10, A29–A33 (2009)
20. Kidney Disease Improving Global Outcomes. KDIGO, Clinical practice guideline for the evaluation and management of chronic kidney disease: Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int. Suppl. 3, 63–72 (2013)
21. Crainiceanu CM, Ruppert D, Wand MP. Bayesian analysis for penalized spline regression using WinBUGS. J. Stat. Software (2005). doi: 10.18637/jss.v014.i14
22. International Diabetes Federation, Diabetes Care and Research in Europe: The St Vincent Declaration 1989. Available from: https://www.idf.org/sites/default/files/StVincentDeclaration1989_WHOEurowandIDFEurope.pdf. Accessed 18 November 2015
23. S.V. Glimianaia, P.W. Tennant, R.W. Bilous, J. Rankin, R. Bell, HbA1c and birthweight in women with pre-conception type 1 and type 2 diabetes: a population-based cohort study, Diabetesologia 55, 3193–3203 (2012)
24. F.D. Johnstone, R.S. Lindsay, J. Steel, Type 1 diabetes and pregnancy: trends in birth weight over 40 years at a single clinic. Obstet. Gynecol. 107, 1297–1302 (2006)
25. D. Kernaghan, G.C. Penney, D.W. Pearson; Scottish Diabetes in Pregnancy Study Group, Birth weight and maternal glycated haemoglobin in pregnancies complicated by type 1 diabetes. Scott. Med. J. 52, 9–12 (2007)
26. M. Klementi, Ntuutila, M. Tikkanen, M.A. Kari, V. Hiilesmaa, K. Teramo, Trends in maternal BMI, glycemic control and perinatal outcome among type 1 diabetic pregnant women in 1989–2008. Diabetesologia 5, 2327–2334 (2012)
27. F.P. Dunne, G. Avalos, M. Durkan, Y. Mitchell, T. Gallacher, M. Keenan, M. Hogan, L.A. Carmody, G. Gaffney; for the ATLANTIC DIP Collaborators, ATLANTIC DIP: Pregnancy outcome for women with pregestational diabetes along the irish atlantic seaboard. Diabetes Care 32, 1205–1206 (2009)
28. L.A. Owens, G. Avalos, L. Kirwan, L. Carmody, F. Dunne; ATLANTIC DIP: closing the Loop, A change in clinical practice can improve outcomes for women with pregestational diabetes. Diabetes Care 35, 1669–1671 (2012)
29. M.J. Maresh, V.A. Holmes, C.C. Patterson, I.S. Young, D.W. Pearson, J.D. Walker, D.R. McCance; Diabetes and Pre-eclampsia Intervention Trial Study Group, Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes. Diabetes Care 38, 34–42 (2015)
30. M.J. O’Kane, P.L. Lynch, K.W. Moles, S.E. Magee, Determination of a diabetes control and complications trial-aligned HbA1c reference range in pregnancy. Clin. Chim. Acta 311, 157–159 (2001)
31. N. Nowak, J. Skupien, K. Cyganek, B. Matejko, M.T. Malecki, 1,5-Anhydroglucitol as a marker of maternal glycemic control and predictor of neonatal birthweight in pregnancies complicated by type 1 diabetes mellitus. Diabetesologia 56, 709–713 (2013)